Nemaura and EVERSANA sign preliminary agreement for large-scale launch of Nemaura’s Diabetes Management Program in the U.S.
September 27 2022 - 8:00AM
Nemaura Medical, Inc.(NASDAQ: NMRD)(“Nemaura” or the “Company”), a
medical technology company focused on developing and
commercialising noninvasive wearable diagnostic devices and
supporting personalized lifestyle coaching programs, today
announces that it has entered into a preliminary agreement with
EVERSANA®, a pioneer of next-generation commercial services to the
global life sciences industry.
The agreement covers the U.S. and all global
sales and marketing of Nemaura’s Diabetes Management Solution,
BEATdiabetes. The BEATdiabetes program is based on Nemaura’s
noninvasive glucose monitoring solution, proBEAT. Nemaura and
EVERSANA will work together to develop the optimal launch strategy
for large-scale adoption of the diabetes management program,
including franchising and direct sales to self-insured corporate
clients and healthcare insurers.
In early pilot trials conducted over the last 12
months, the BEATdiabetes program yielded overall positive outcomes,
demonstrating that sustainable, long-term weight loss and,
therefore, improvement in the management of Type 2 diabetes is
achievable. Incumbents in the space have also demonstrated
clinically significant outcomes when such diabetes management
programs are used in conjunction with continuous glucose monitors.
Nemaura, however, has the advantage of its own proprietary
noninvasive sensor technology which significantly reduces sensor
costs, as the sensors are only worn a few days each month.
EVERSANA is widely regarded as the leader in
digital therapeutic commercialization. Across the life sciences
industry, the fully integrated commercialization provider works
with more than 670 organizations, including innovative start-ups
and established pharmaceutical companies.
Dr. Faz Chowdhury, Nemaura Medical’s Chief
Executive Officer, stated, “We are excited to be working with
EVERSANA to bring our diabetes management solution to market. This
is a culmination of several months of negotiations with EVERSANA
following the encouraging outcome of the pilot studies. Diabetes
management is an area of huge unmet need, and we anticipate that
our solution will be very easy, simple to administer, and highly
cost-effective, all elements supporting large-scale adoption.”
Jim Lang, Chief Executive Officer of EVERSANA,
added, “Nemaura’s innovative programs and sensor technology
potentially represent a major change in the way in which diabetes
is addressed and how patients may be supported. We look forward to
leveraging our full suite of commercialization services to support
a successful U.S. launch.”
About Nemaura Medical, Inc.
Nemaura Medical Inc. is a medical technology
company developing and commercialising noninvasive wearable
diagnostic devices. The company is currently commercialising
sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb
medical device, is a noninvasive and flexible continuous glucose
monitor (CGM) providing actionable insights derived from real time
glucose measurements and daily glucose trend data, which may help
people with diabetes and prediabetes to better manage, reverse, and
prevent the onset of diabetes. Nemaura has submitted a PMA
(Premarket Approval Application) for sugarBEAT® to the U.S. FDA.
proBEAT™ combines noninvasive glucose data processed using
artificial intelligence and a digital healthcare subscription
service that has been launched in the U.S. as a general wellness
product as part of its BEAT® diabetes program that is currently
undergoing pilot studies.
The Company sits at the intersection of the
global Type 2 diabetes market that is expected to reach nearly $59
billion by 2025, the $50+ billion pre-diabetic market, and the
wearable health-tech sector for weight loss and wellness
applications that is estimated to reach $60 billion by 2023.
For more information, please visit www.NemauraMedical.com.
About EVERSANA™
EVERSANA™ is a leading independent provider of
global services to the life sciences industry. The company’s
integrated solutions are rooted in the patient experience and span
all stages of the product life cycle to deliver long-term,
sustainable value for patients, prescribers, channel partners, and
payers. The company serves more than 670 organizations, including
innovative start-ups and established pharmaceutical companies, to
advance life sciences solutions for a healthier world. To learn
more about EVERSANA, visit eversana.com or connect
through LinkedIn and Twitter.
Media Contacts
Jules AbrahamCORE IR+1 917-885-7378
EVERSANAMatt BraunDirector, Corporate
Communicationsmatt.braun@eversana.com+1 414-434-4830
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Sep 2023 to Sep 2024